2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue.
Vertex Pharmaceuticals Drug Administration Bluebird Bio Motley Fool Stock Advisor Stock Advisor Hematologic Malignancy
Source: yahoo.com
📰 Hematologic Malignancy News
Hematologic Malignancy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hematologic Malignancy. Real-time updates on events, politics, business and more.
Should You Invest in Bluebird Bio Right Now?
After two December share price crashes, there's no evident cure for Bluebird Bio's ills.
Warren Buffett Mani Foroohar Benjamin Graham Vertex Pharmaceuticals Drug Administration Bluebird Bio
Source: yahoo.com
Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)
1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% of fatalities were thought to be due to liso-cel related complications. Evidence Rating Level: 1 (Excellent) Study Rundown: There exist limited options for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic
United States Rating Level First Line Venetoclax Combinations Chronic Lymphocytic Between Jan Chronic Lymphocytic Leukemia
Source: 2minutemedicine.com
The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, today announced that Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), Stemline's development partner in Japan, received Orphan Drug Designation for tagraxofusp, from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the expected indication of blastic plasmacytoid dendritic c...
United States Elcin Barker Ergun Menarini Industrie Farmaceutiche Riunite Stemline Therapeutics Inc World Health Organization Menarini Group
Source: yahoo.com
Dr Mead on the Use of Zanubrutinib vs Ibrutinib in MCL
Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.
Los Angeles United States Monicad Mead University Of California Jonsson Comprehensive Cancer Center Hematologic Malignancy
Source: onclive.com
Dr Mead on the Decreased Use of Ibrutinib in Pretreated MCL
Monica D. Mead, MD, discusses reasons for the declining use of the BTK inhibitor ibrutinib in patients with mantle cell lymphoma.
Los Angeles United States Monicad Mead National Comprehensive Cancer Network University Of California Jonsson Comprehensive Cancer Center
Source: onclive.com
Dr Mead on the Shifting Role of Ibrutinib in the Treatment of MCL
Monica D. Mead, MD, discusses the impact of key data on the role of ibrutinib in the treatment of mantle cell lymphoma.
United States Los Angeles Monicad Mead University Of California Jonsson Comprehensive Cancer Center Department Of Hematologic Malignancy
Source: onclive.com
Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma
Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL
United States Los Angeles Martin Dreyling Monicad Mead University Of California Jonsson Comprehensive Cancer Center
Source: onclive.com
Quizartinib improves overall median survival in patients with acute myeloid leukemia
1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion of adverse events in both groups was comparable between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute myeloid leukemia (AML) is an aggressive form of blood cancer with poor clinical outcomes. In patients with
Rating Level Previously Untreated Acute Myeloid Between Sept Acute Myeloid Leukemia Blood Cancer Hematologic Malignancy
Source: 2minutemedicine.com
GRAIL, LLC: GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023
GRAIL's Methylation Assay Had 92% Cancer Detection Rate Across Six Hematologic Malignancies With 96% Accuracy in Determining the Hematologic Malignancy Subtype Findings Support Use of GRAIL's Methylation
Source: finanznachrichten.de